News

Winners for the 2013 CPhI Pharma Awards, which recognize pharmaceutical innovation, will be awarded on later today, Tuesday Oct. 22.

The Aenova Group will merge with Haupt Pharma, a company specializing in contract development and manufacturing.

FDA is seeking a permanent injunction against a dietary supplement manufacturer following the company?s repeated distribution of unapproved drugs and adulterated dietary supplements.

FDA has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases.

Capsule design was developed for patients who have difficulty swallowing.

Novozymes Biopharma will collaborate with Almac to provide a combined service for drug development applications.

Abbott?s third-quarter 2013 global sales increased slightly but were affected by a disruption in the International Nutrition business.

Interview of Detlev Haack, head of R&D, Hermes Pharma on the characteristics, benefits and manufacturing Methods of effervescent tablets

J&J announces 2013 third-quarter sales increased 3% over 2012 third-quarter sales.

MedPharm opens a new topical and transdermal formulation-development services facility in Guildford, United Kingdom.

The CDMOs DPT Laboratories and Confab will integrate under the leadership of Paul Johnson, group president and COO.

Penn Pharma partners with GEA Pharma to open a new facility for the development and manufacture of oncology drugs.

The success of Adcetris and Kadcyla is paving the way for more antibody drug conjugates to enter the market, especially in the treatment of solid tumors.

ISPE has announced the results of its 2013-2014 International Board of Directors election.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

The FDA grants Cornerstone Pharmaceuticals orphan drug designation for CPI-613 for the treatment of myelodysplastic syndrome.

Roche's plans for a major biologics manufacturing expansion is the latest investment by Big Pharma

Kansas State University to build Bulk Solids Innovation Center in Salina, Kansas.

AstraZeneca and SAFC are the latest companies to expand positions in antibody drug conjugates (ADCs).

CPhI Worldwide starts off with a conference program on Monday 21 October.

The US Pharmacopeial Convention posted for public comments on its revisions to the USP Medicare Model Guidelines, which are posted for a 30-day public comment period, beginning Oct. 1, 2013.

Capacity expansions and new products meet needs for inhaler and injector systems.

The UK regulatory agency issues statement of noncompliance against Wockhardt?s site in Chikalthana, India and Wockhardt?s contract manufacturer Nestor in the United Kingdom.

Governor Jerry Brown cites physician notification requirements for dispensing biosimilars as premature in the absence of FDA specifications for interchangeability.

Genzyme will build a facility in Massachusetts to expand purification capacity for Fabrazyme (agalsidase beta).

Adeline Siew Scientific Editor of Pharmaceutical Technology and Pharmaceutical Technology Europe talks to Joe Galati, Manager, Toxicology Services, Marvin Faber, Sr. Director, Global Head Environmental Health & Safety (EH&S), and Jeff Dinyer, Director EH&S & Global all from Patheon

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

Challenges in the formulation and manufacturing process of fixed-dose combinations

GT Biologics has been granted orphan drug designation by FDA Office of Orphan Product Development for Thetanix,

OncoMed Pharmaceuticals has been granted its first US patent on its MAbTrap antibody display technology.